GlassScriptPhysician profile
Chih C Chang
NPI 1104835958
$9,477.42
in general payments reported to CMS, 2019-2025
49 companies · $736 in 2025
The $736 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,599 · 2020: $1,057 · 2021: $1,315 · 2022: $1,449 · 2023: $2,031 · 2024: $1,291 · 2025: $736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Travel and Lodging: $652 · Education: $37.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.13 |
| Travel and Lodging | $651.97 |
| Education | $37.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,539.35 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Novo Nordisk INC | $1,095.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,024.87 | 2019-2024 | Jardiance, Mounjaro, Lyumjev |
| Amgen INC. | $712.26 | 2019-2025 | Repatha, Prolia, Evenity |
| Abbott Laboratories | $454.94 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $379.20 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $337.79 | 2019-2025 | Tradjenta, Jardiance, Synjardy |
| Dexcom, INC. | $327.26 | 2019-2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $325.45 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $314.45 | 2019-2023 | Januvia, Steglatro |
| Insulet Corporation | $237.02 | 2022-2025 | Omnipod, Omnipod |
| Xeris Pharmaceuticals, INC. | $198.03 | 2020-2023 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $194.64 | 2021-2022 | |
| Pfizer INC. | $183.78 | 2020-2023 | |
| Antares Pharma, INC. | $158.32 | 2019-2023 | Nocdurna, Tlando, Xyosted |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chih Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.